Work

Prevention of cardiovascular disease in type-2 diabetes: How to improve the clinical efficacy of aspirin

Year: 2005
Type: review
Abstract: Atherosclerotic cardiovascular disease and its thrombotic complications are the principal causes of morbidity and mortality in patients with type-2 diabetes. Aspirin reduces the risk of thrombotic events in a broad range of patients with vascular disease and, in selected individuals, is beneficial for primary prevention. Although recommended by existing guidelines, in secondary and in primary prevention trials the clinical efficacy of low-dose aspirin in patients with diabetes appears to be substantially lower than in individuals without diabetes. In this review, we discuss possible mechanisms that may contribute to reduce the antithrombotic activity of aspirin in diabetes. We also discuss adjuvant therapies used in diabetic patients that may potentially improve the antithrombotic efficacy of aspirin.
Language: English
Field: Medicine
Open Access status: bronze
OpenAlex ID: W2155922543
FWCI: 1.651
Cites: 135
Cited by: 63
Related to: 10